Influenza kills hundreds of thousands of people around the world every year, yet there is essentially only one class of drugs to fight the ever-changing virus. Cases of flu resistant to this class of drugs have already been reported and researchers worry a completely new strain of flu could evolve, leading to a pandemic like the one in 1918 that killed approximately 50 million people. Many researchers are trying to develop new drugs to defeat the flu virus. But researchers at St. Michael's Hospital had a completely different idea.
People who die from the flu actually die from respiratory failure, when the lung's tiny blood vessels start leaking fluid into the lung's air sacs. Dr. Warren Lee, a researcher with the hospital's Keenan Research Centre for Biomedical Sciences, wondered what would happen if someone developed a treatment that would prevent those blood vessels from leaking?
Working with mice, Lee tested a new drug developed by researchers at Sunnybrook Hospital that acts on the endothelial cells that line the blood vessels.
Their work, published today in the journal Scientific Reports, found that:
The drug, Vasculotide, was effective against multiple strains of influenza, including the 2009 swine flu pandemic strain. Without the drug, 100 per cent of the mice died within one week. With the drug, more than 80 per cent survived. In addition:
•The drug worked even if it was administered days after the infection began. Traditional antiviral drugs such as Tamiflu must be started immediately.
•The drug worked alone and in combination with antivirals.
•It worked without compromising the body's ability to mount an immune response to the virus.
Lee, a critical-care physician and cell biologist, says that while this research was conducted in mice, he found the results exciting since the drug was effective in two different strains of mice and three different strains of flu. He said that since the mechanism of blood vessels leaking into lungs is common throughout animals, he was optimistic the drug could be effective in animals other than mice, including humans.
St. Michael's and Sunnybrook have jointly applied for a U.S. patent for the drug.
This study received funding from the Canadian Institutes of Health Research, the Physicians' Services Incorporated Foundation and a Government of Ontario Early Researcher Award.
Source: St. Michael's Hospital
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.